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A B S T R A C T   
11β-hydroxysteroid dehydrogenase 2 (11β-HSD2) converts active 11β-hydroxyglucocorticoids to their inactive 
11-keto forms, thereby preventing inappropriate mineralocorticoid receptor activation by glucocorticoids. 
Disruption of 11β-HSD2 activity by genetic defects or inhibitors causes the syndrome of apparent mineralocor-
ticoid excess (AME), characterized by hypokalemia, hypernatremia and hypertension. Recently, the azole anti-
fungals itraconazole and posaconazole were identified to potently inhibit human 11β-HSD2, and several case 
studies described patients with acquired AME. To begin to understand why this adverse drug effect was missed 
during preclinical investigations, the inhibitory potential of itraconazole, its main metabolite hydroxyi-
traconazole (OHI) and posaconazole against 11β-HSD2 from human and three commonly used experimental 
animals was assessed. Whilst human 11β-HSD2 was potently inhibited by all three compounds (IC50 values in the 
nanomolar range), the rat enzyme was moderately inhibited (1.5- to 6-fold higher IC50 values compared to 
human), and mouse and zebrafish 11β-HSD2 were very weakly inhibited (IC50 values above 7 μM). Sequence 
alignment and application of newly generated homology models for human and mouse 11β-HSD2 revealed 
significant differences in the C-terminal region and the substrate binding pocket. Exchange of the C-terminus and 
substitution of residues Leu170,Ile172 in mouse 11β-HSD2 by the corresponding residues His170,Glu172 of the 
human enzyme resulted in a gain of sensitivity to itraconazole and posaconazole, resembling human 11β-HSD2. 
The results provide an explanation for the observed species-specific 11β-HSD2 inhibition by the studied azole 
antifungals. The obtained structure-activity relationship information should facilitate future assessments of 11β- 
HSD2 inhibitors and aid choosing adequate animal models for efficacy and safety studies.   
1. Introduction 
11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) catalyzes the 
oxidation of potent 11β-hydroxyglucocorticoids (cortisol in human and 
fish, corticosterone in rodents) to inactive 11-ketoglucocorticoids 
(cortisone in human and fish, 11-dehydrocorticosterone in rodents). In 
mineralocorticoid target tissues such as kidney, colon, salivary and 
sweat glands, 11β-HSD2 has a gate-keeper function to regulate the ac-
cess of cortisol to mineralocorticoid receptors (MR), thereby allowing 
specificity of aldosterone to activate MR (Edwards et al. 1988; Funder 
et al. 1988; Odermatt and Kratschmar 2012). By this mechanism, 11β- 
HSD2 has an important role in the regulation of the electrolyte balance. 
Loss of function mutations in the gene encoding 11β-HSD2 lead to the 
syndrome of apparent mineralocorticoid excess (AME), caused by 
excessive MR activation by cortisol (Mune et al. 1995; Wilson et al. 
1995; White et al. 1997). These patients suffer from pseudohyper-
aldosteronism with hypokalemia, hypernatremia, water retention and 
hypertension, with typically low renin and aldosterone levels along with 
increased plasma and urinary cortisol to cortisone ratios. Acquired forms 
of AME can be caused by the excessive consumption of licorice, con-
taining the potent 11β-HSD inhibitor glycyrrhetinic acid (GA) (reviewed 
in (Ferrari 2010)), and, as more recently reported, by the systemically 
administered azole antifungals posaconazole and itraconazole 
(Thompson et al., 2017; Barton et al. 2018; Boughton et al. 2018; 
Abbreviations: 11β-HSD2, 11β-hydroxysteroid dehydrogenase type 2; AME, Apparent mineralocorticoid excess; C-terminal, Carboxy-terminal; GA, Glycyrrhetinic 
acid; MR, Mineralocorticoid receptors; OHI, Hydroxyitraconazole; WT, Wild type. 
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Hoffmann et al. 2018; Wassermann et al. 2018; Thompson et al., 2019). 
11β-HSD2 is also highly expressed in the placenta, where it exerts a 
barrier function to protect the developing fetus from high maternal 
cortisol concentrations (Albiston et al. 1994; Stewart et al. 1995). In-
hibition of placental 11β-HSD2 is associated with intra-uterine growth 
restriction and results in an increased risk for cardio-metabolic diseases 
in later life of the off-spring (Edwards et al. 1993; Lindsay et al. 1996; 
Seckl et al. 2000; Odermatt 2004). Given its important physiological 
functions, it is crucial to identify exogenous substances inhibiting 11β- 
HSD2 that might cause adverse health effects in human. Furthermore, 
11β-HSD2 was recently found to be involved in oxysterol metabolism, 
with possible roles in the regulation of the immune system and in the 
control of cancer cell properties (Voisin et al. 2017; Raleigh et al. 2018; 
Beck et al. 2019a; Beck et al. 2019b). However, whether a disturbance of 
these functions contributes to the observed adverse health effects upon 
inhibition of 11β-HSD2 remains unknown. 
Animal models are widely applied for efficacy and safety studies 
during the development and testing of novel drugs. However, the fact 
that the itraconazole- and posaconazole-induced pseudohyperaldoster-
onism remained undetected in preclinical investigations emphasizes the 
importance to understand species-specific differences as well as caution 
when trying to extrapolate findings from animal studies to human. The 
most frequently used animal species for preclinical toxicological studies 
is the rat, whereas the mouse is most widely used for mechanistic in-
vestigations, including transgenic lines. Additionally, the importance of 
zebrafish has gained considerable attraction due to the low cost and 
because experiments with larvae during the first 96 h are not considered 
as animal experiment (Planchart et al. 2016; Wrighton et al. 2019). 
Rather few studies addressed species-specific differences in 11β- 
HSD2 so far. Nevertheless, in vitro studies showed potent inhibitory ef-
fects of the anabolic androgenic steroid fluoxymesterone (Fürstenberger 
et al. 2012) and of dithiocarbamates (Meyer et al. 2012) against human 
but not rodent or zebrafish 11β-HSD2, respectively. Furthermore, itra-
conazole and posaconazole were shown to be potent inhibitors of re-
combinant human 11β-HSD2 in in vitro experiments (Beck et al. 2017), 
whereas measurements performed in whole rat an mouse kidney ho-
mogenates suggested much weaker inhibitory effects in these species. 
However, in whole renal homogenates the compounds could have been 
metabolized and therefore no longer able to inhibit 11β-HSD2 activity, 
thus requiring a direct comparison of inhibitory effects on recombinant 
enzymes determined in the same cellular background. Nevertheless, no 
significant adverse effects were observed after inspection of endocrine 
parameters in preclinical rat studies following exposure to itraconazole 
(Van Cauteren et al. 1987). This suggests that due to species-differences 
rodents may not serve as suitable surrogate models to study effects on 
11β-HSD2 in human. 
The present study aimed to compare inhibitory potencies of pos-
aconazole, itraconazole and its main metabolite hydroxyitraconazole 
(OHI) towards recombinant human, rat, mouse and zebrafish 11β-HSD2. 
A more detailed comparison then focused on the human and mouse 
enzyme. For this purpose, new homology models, molecular docking 
calculations as well as site-directed mutagenesis and enzyme activity 
assays with chimeric proteins were applied to elucidate the structure- 
function relationships of the species-specific differences in the mecha-
nism of inhibition by the azole antifungals. 
2. Material and methods 
2.1. Chemicals and reagents 
[1,2,6,7-3H]-cortisol was obtained from Perkin-Elmer (Boston, MA, 
USA) and hydroxyitraconazole (OHI) from Carbosynth (Berkshire, UK). 
All other chemicals were from Sigma-Aldrich (Buchs, Switzerland) if not 
stated otherwise. 
2.2. Cell culture 
Human embryonic kidney-293 cells (HEK-293) were purchased from 
ATCC (Manassas, VA, USA). Cells were cultured in Dulbecco’s modified 
Eagle medium (DMEM) supplemented with 4.5 g/L glucose, 10% fetal 
bovine serum (S1810-500, Biowest, Nuaillé, France), 100 U/mL peni-
cillin, 0.1 mg/mL streptomycin, 10 mM HEPES buffer (pH 7.4) and 1% 
MEM non-essential amino acids (Bio Concept, Allschwil, Switzerland) at 
standard conditions (37 ◦C and humidified 5% CO2). 
2.3. Molecular cloning 
All chimeric proteins were designed to bear a C-terminal Flag-tag 
(DYKDDDDK) and were cloned into the pcDNA3.1 vector (Invitrogen, 
Carlsbad, CA, USA) (schematic overview of the chimera in Fig. 3). The 
chimera A (human 11β-HSD2 with mouse C-terminus), B (mouse 11β- 
HSD2 with human C-terminus), C (human 11β-HSD2 with mouse 
cassette) and D (mouse 11β-HSD2 with human cassette) were generated 
by a sequence overlap extension approach based on the human (Oder-
matt et al. 1999) or mouse 11β-HSD2 cDNA (NM_008289.2 in pcDNA3.1 
from GenScript, Piscataway Township, NJ, USA). The fragments were 
amplified with complementary overhangs of the cassette corresponding 
to residues 268–277 for human (5’-GAGTCAGTGA-
GAAACGTGGGTCAGTGGGAA-3′) and mouse 11β-HSD2 (5’-GATG-
CAGTGACTAATGTGAACCTCTGGGAG-3′) (oligonucleotide primers 
used for amplification are shown in Suppl. Table 1). The two purified 
fragments containing the complementary overhangs were supplied in an 
equimolar ratio, followed by a PCR reaction using primers at the 5′ and 
3′ end of the entire sequence for amplification. PCR reactions were 
carried out using iProof™ High-Fidelity DNA polymerase (Bio-rad, 
Hercules, CA, USA). The final PCR product was digested with Hind-III 
HF and Kpn-I HF (New England Biolabs, NEB, Ipswich, MA, USA) and 
ligated into pcDNA3 by T4 ligase (NEB). 
Chimera E (human 11β-HSD2 with His170Leu,Glu172Ile) and G 
(chimera A with His170Leu,Glu172Ile) were obtained by site directed 
mutagenesis using Pfu polymerase (NEB) and TaKaRa PrimeSTAR GXL 
polymerase (Takara Bio Inc., Kusatsu, Japan). Oligonucleotide primers 
were designed to achieve a circular nicked PCR-product. Template DNA 
was removed by a Dpn I digest (NEB), and the PCR product was trans-
formed into competent bacterial cells for amplification. Chimera F 
(mouse 11β-HSD2 bearing mutations Leu170His,Ile172Glu) and H 
(chimera B with mutations Leu170His,Ile172Glu) were generated uti-
lizing iProof ™ High-Fidelity DNA polymerase, resulting in a linear 
unphosphorylated PCR-product. To facilitate re-circularization, the 5′- 
ends were phosphorylated by T4 polynucleotide kinase (NEB) prior to 
ligation by T4 ligase. After Dpn I digest, the clones were transformed 
into competent bacterial cells. Sequences were verified by Sanger 
sequencing (Microsynth, Balgach, Switzerland). 
2.4. Determination of the inhibition of wild type and mutant 11β-HSD2 
activity by azole antifungals 
HEK-293 cells (2 × 106 cells per 10 cm cell culture dish) were 
incubated for 24 h and transiently transfected with plasmids encoding 
mouse (NM_008289.2), rat (NM_017081.2) or zebrafish 11β-HSD2 
(NM_212720.2), or with chimera A-H, using the calcium precipitation 
method. All constructs were C-terminally flag epitope tagged and cloned 
into pcDNA3. At 48 h post-transfection, the cells were washed with PBS, 
collected in 2 mL ice-cold PBS per 10 cm dish, aliquoted (200 μL or 400 
μL) and centrifuged at 4 ◦C for 4 min at 16,000 × g. Subsequently, su-
pernatants were discarded, pellets shock-frozen and stored at − 80 ◦C. 
For the analysis of human 11β-HSD2 activity, HEK-293 cells stably 
expressing 11β-HSD2 (AT8 clone) were utilized as described earlier 
(Inderbinen et al., 2020). Cell pellets were suspended in 400 μL TS2 
buffer (NaCl 100 mM, EGTA 1 mM, EDTA 1 mM, MgCl2 1 mM, sucrose 
250 mM, Tris-HCl 20 mM, pH 7.4) and lysed by sonication (UP50H 
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sonicator, Hielscher Ultrasonics). Conditions for each batch of cell pel-
lets were optimized to reach 20–30% substrate to product conversion 
rate. Lysates were incubated with test substances or vehicle control 
(DMSO), 50 nM cortisol (containing 10 nCi of [1,2,6,7-3H] cortisol) and 
500 μM NAD+ in a total volume of 22 μL TS2 buffer at 37 ◦C. The DMSO 
concentration was kept below 1.2%. At this concentration the solvent 
did not affect enzyme activity. After 10 min (human, chimera B) or 20 
min (mouse, rat, zebrafish, chimera A, C, D, E, F and H), reactions were 
stopped by adding excess amounts of unlabeled cortisone and cortisol in 
methanol (1:1, 2 mM each). Samples were separated by thin-layer 
chromatography (mobile phase chloroform/methanol; 9:1), dissolved 
in scintillation cocktail (IRGASAFE Plus, Zinsser Analytic, Frankfurt am 
Main, Germany) and radioactivity was measured by liquid scintillation 
counting (Packard, Connecticut, USA). Experiments were repeated at 
least three times independently and data were normalized to vehicle 
control. 
2.5. Homology model and docking 
As there is no crystal structure of 11β-HSD2 available to date, the 
modeling study aiming at explaining the mechanism of inhibition of the 
human and mouse enzyme variants was initiated with homology 
modeling using the SwissModel homology modeling platform 
(https://swissmodel.expasy.org). The primary FASTA sequence of 
human 11β-HSD2 was used as input to the SwissModel web-server. Up to 
thirty homology models were built based on templates identified by 
sequence similarity to existing proteins. 
Eight homology models were built using template structures of 17β- 
HSD1 (various PDB IDs), twenty models were based on the template 
structure of 11β-HSD1 (various PDB IDs), one model on the template 
structure of 3-oxoacyl-[acyl-carrier-protein] reductase (PDB ID: 3u9l) 
and finally one on the template structure of a putative short chain de-
hydrogenase (PDB ID: 5u4s). 
Visual inspection of eight models based on template structures of 
17β-HSD1 yielded no satisfactory model with respect to the placement of 
both the substrate and cofactor NAD+ and the dehydrogenation reaction 
that the enzyme is supposed to catalyze (at position 11). The assumed 
pose of the cofactor within the active site was found to interfere with 
backbone elements of the built homology models, rendering them un-
suitable for further processing. This is in contrast with a previous study 
that, however, used a complex multi-step refinement and optimization 
procedure to obtain a valid putative model (Yau et al. 2017). 
Therefore, we focused on twenty homology models based on the 
template structure of 11β-HSD1, i.e. the closest relative in this enzyme 
family. Their Global Model Quality Estimation (GMQE) scores did not 
differ substantially from those of the 17β-HSD1 based models (0.40 vs 
0.44 for the best scored models). Both cofactor (NAD+) and substrate 
(cortisol) poses were reconstructed by a rigid body transfer and subse-
quent structure modification from the 11β-HSD1 structure with the PDB 
ID 1y5r (cofactor, NADPH; ligand, corticosterone) after protein align-
ment. Most of the 11β-HSD-based models did not show any unfavorable 
steric backbone clashes with the assumed cofactor pose and allowed 
placing of the natural substrate into the active site. In analogy to human 
11β-HSD2 models, we built thirty homology models using the mouse 
FASTA sequence. For both species, homology models based on guinea 
pig 11β-HSD1 (PDB ID: 3g49) revealed the most reliable models that 
were utilized for further investigations. 
The structure-activity relationships-conform binding modes of the 
natural substrate cortisol at both human and mouse homology models 
were found by manual docking. As mentioned earlier, the corticosterone 
pose relative to the nicotinamide moiety of NAD+ and key catalytic 
residues Tyr232 and Ser219, as it occurs in homologous 11β-HSD1 
structure with PBD ID 1y5r, was used as a reference starting point. The 
17α-hydroxy group was added, turning corticosterone to cortisol, and 
together with the hydroxymethylcarbonyl group at position 17β ori-
ented for the most optimal interaction with the nearby backbone, 
cofactor and side-chain (in this order of preference) H-bond donors and 
acceptors. As the C-terminal part of 11β-HSD2 interacting with azole 
fungicides could not be sufficiently resolved in homology modeling, only 
the 1-(butan-2-yl)-4-phenyl-4,5-dihydro-1H-1,2,4-triazol-5-one part of 
itraconazole responsible for the sensitivity towards 11β-HSD2 was 
manually docked. The binding mode was constructed by satisfying the 
carbonyl H-bond acceptor with a properly directional hydrogen bond 
donor from Tyr232 while paying attention to minimizing the steric 
clashes with the other residues in the active site. The manual docking 
was performed in Maestro modeling environment (Maestro, version 
10.4, Schrödinger, LLC, New York, NY, 2015). Protein Preparation 
Wizard minimizer routine with OPLS_2005 force field was used to relax 
manually constructed protein-ligand complexes and Maestro was used 
for visualization (Sastry et al. 2013). 
2.6. Statistical analysis 
Data were analyzed using two-way ANOVA with Bonferroni’s post 
hoc tests in the GraphPad Prism 5 software. Values represent mean ± SD. 
3. Results 
3.1. Species-specific differences in the inhibition of 11β-HSD2 by 
posaconazole, itraconazole and OHI 
The posaconazole-, itraconazole- and OHI-dependent inhibition of 
cortisol oxidation by 11β-HSD2 from the four different species human, 
mouse, rat and zebrafish was determined in lysates of HEK-293 cells 
expressing recombinant enzyme (Fig. 1, Table 1). Itraconazole, OHI and 
posaconazole potently inhibited the human enzyme, with IC50 values of 
121 ± 30, 187 ± 56 and 512 ± 79 nM, respectively. Itraconazole and 
OHI were approximately 6-fold less active towards the rat enzyme, 
whereas posaconazole was only 1.6-fold less active. In contrast, all three 
azole antifungals showed only very weak inhibitory effects towards 
mouse and zebrafish 11β-HSD2, with IC50 values above 7 μM. 
3.2. Comparison of human, mouse, rat and zebrafish 11β-HSD2 protein 
sequences 
To begin to understand which regions of the sequence are respon-
sible for the observed species-specific differences in 11β-HSD2 inhibi-
tion by the azole antifungals, the protein sequences of human, mouse, 
rat and zebrafish 11β-HSD2 were aligned (Fig. 2). The justbio (justbio. 
com) alignment tool was utilized to analyze protein sequences 
(human: NP_000187.3; mouse: NP_032315.2; rat: NP_058777.1; zebra-
fish: NP_997885). The catalytic triad Ser219, Tyr232 and Lys236, the 
cofactor-binding site in the Rossmann-fold (Gly89-X-X-X-Gly93-X- 
Gly95) and most of the α-helices and β-sheets are conserved among the 
four species. As expected, human 11β-HSD2 shares higher sequence 
similarities with mouse and rat enzymes than with that of the zebrafish. 
Significant differences were detected in the C-terminal regions. The 
mouse enzyme is 19 amino acids shorter than its human counterpart, 
while the rat C-terminus is more similar to that of the human enzyme. 
Thus, we hypothesized that the variable C-terminal region could be 
responsible for the differences in the inhibition of human and mouse 
11β-HSD2 by the investigated azole fungicides. Previous predictions 
using rigid homology models of the human and mouse enzyme sug-
gested a different orientation of Trp276 that would cause steric hin-
drance in the mouse enzyme and prevent binding of posaconazole, 
itraconazole and OHI (Beck et al. 2017). Additionally, Arg279 was 
proposed to stabilize the binding of itraconazole and OHI in the human 
enzyme but not in mouse 11β-HSD2, where this residue did not seem to 
form interactions with the investigated azole fungicides (Beck et al. 
2017; Beck et al. 2020a). Interestingly, Trp276 and Arg279 are both 
conserved in human and mouse 11β-HSD2. Nevertheless, a closer in-
spection of the sequence upstream of these two amino acids led to the 
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hypothesis that the rather bulky amino acids Arg271 and Gln275 in 
human compared to Thr271 and Leu275 in mouse 11β-HSD2 might 
result in a different orientation of Trp276 and Arg279 in the two species. 
Thus, in a next step, the species difference between human and mouse 
11β-HSD2 was investigated by site-directed mutagenesis and generation 
of chimeric proteins. 
3.3. The role of the C-terminal region and of residues 268–277 on the 
inhibition of human and mouse 11β-HSD2 by azole fungicides 
Four different chimera were constructed to investigate the role of the 
C-terminus in the different response of human and mouse 11β-HSD2 to 
the azole antifungals (Fig. 3A). Chimera A contains the sequence of 
human 11β-HSD2 up to residue 268, followed by the mouse C-terminus. 
Chimera B represents the complementary construct with the mouse 
sequence up to position 268, followed by the human C-terminus. To 
investigate the impact of the amino acids 268–277 on the orientation of 
Trp276 and Arg279, this cassette of 8 amino acids was exchanged be-
tween human and mouse, resulting in chimera C (human enzyme with 
the mouse cassette) and D (mouse enzyme with the human cassette). 
These chimeric proteins were expressed similar to the wild type enzymes 
and able to convert cortisol to cortisone (Suppl. Fig. 1). 
We hypothesized that chimera A and C would show a loss of inhi-
bition by the azole fungicides compared to human 11β-HSD2 and that 
chimera B and D would show a gain of inhibitory effect compared to the 
mouse enzyme. Therefore, lysates of HEK-293 cells expressing the 
respective protein were subjected to enzyme activity assays in the 
absence and presence of 1 μM or 10 μM of the indicated azole fungicide 
(Fig. 4). Substitution of the human C-terminal region by that of the 
mouse enzyme in chimera A significantly decreased the inhibitory effect 
of the tested azole fungicides (Fig. 4). The analogous substitution, i.e. 
mouse enzyme bearing the human C-terminal region (chimera B), 
resulted in a trend to increased sensitivity towards itraconazole but not 
towards posaconazole or OHI (Figure 4Fig. 4). Substitution of the human 
sequence upstream of Trp276 by the corresponding mouse cassette 
(chimera C) as well as the analogous exchange in the mouse enzyme 
(chimera D) did not affect the azole fungicide-mediated inhibition (data 
not shown). 
3.4. Use of homology models to study differences between human and 
mouse 11β-HSD2 
Due to the limitations of previously used rigid homology models, 
more flexible models of human and mouse 11β-HSD2 were developed to 
study further species-specific differences. The new models both pre-
dicted comparable hydrogen bonds between Ser219 and Tyr232 with 
the C11-hydroxyl on cortisol and the cofactor, essential for catalytic 
activity (Fig. 5, Video 1 and Video 2). Additionally, Tyr226 forms a 
hydrogen bond with the C3‑carbonyl on cortisol, and the C21-hydroxyl 
on cortisol forms a hydrogen bond with NAD+ in both species. Predicted 
differences include hydrogen bonds between Gln342 and the 
C3‑carbonyl on cortisol as well as between NAD+ and Ser269 in human 
11β-HSD2 that are both absent in the mouse enzyme. Furthermore, 
Ser269 forms a hydrogen bond with the C17-hydroxyl on cortisol, while 
the mouse enzyme has an alanine at this position. Notably, the new 
models predicted differences in the orientation and interactions of the 
loop consisting of residues 168–180 that are lining the active site. A 
Fig. 1. Inhibition of human, mouse, rat and zebrafish 11β-HSD2 activity. Ly-
sates of HEK-293 cells expressing recombinant 11β-HSD2 of the respective 
species were incubated for 10 min (human) or 20 min (mouse, rat, zebrafish) in 
the presence of 50 nM cortisol, 500 μM NAD+ and increasing concentrations of 
posaconazole (A), itraconazole (B) or OHI (C). Substrate conversion was 
normalized to that of the vehicle control (DMSO; 0.3% for posaconazole, 0.6% 
for itraconazole and 1.2% for OHI). Inhibition curves were fitted and analyzed 
by non-linear regression. Data shown are from at least three independent ex-
periments and represent mean ± SD. 
Table 1 
IC50 values for human, mouse, rat and zebrafish 11β-HSD2 of posaconazole, 
itraconazole and OHI. 11β-HSD2 activity was determined in lysates of HEK-293 
cells expressing the recombinant enzyme of the respective species. The con-
version of cortisol to cortisone was measured in the presence of increasing 
concentrations of inhibitor. Inhibition curves were fitted and analyzed by non- 
linear regression. Data were normalized to vehicle control and represent 
mean ± SD of at least three independent experiments. * % remaining activity at 
the highest concentration of 30 μM.   
Inhibition of 11β-HSD2 activity: IC50 [μM]  
Human Mouse Rat Zebrafish 
Posaconazole 0.512 ± 0.079 8.21 ± 0.56 0.835 ± 0.142 10.1 ± 0.5 
Itraconazole 0.121 ± 0.030 (95%)* 0.729 ± 0.592 9.80 ± 1.96 
OHI 0.187 ± 0.056 11.9 ± 2.5 1.13 ± 0.96 7.48 ± 1.68  
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Fig. 2. Alignment of human, mouse, rat and zebrafish 11β-HSD2 protein sequences. Symbols are coded as followed: grey arrow, α-helix; black arrow, β-sheets; 
rectangles, cofactor-binding site in the Rossmann-fold, and positions 170, 172, 276 and 279; underlined and bold letter, active site; (*), fully conserved residues; (:), 
residues with considerably similar properties; (.), residues with moderately similar properties. 
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closer look in human 11β-HSD2 on the binding site region in the vicinity 
of the steroid substrate D-ring, dictating selectivity to cortisol, indicated 
that the loop portion around histidine residue 170 (His170) could be 
responsible for interspecies differences in the enzyme selectivity. Opti-
mization of a human homology model built on the guinea pig 11β-HSD1 
(PDB ID: 3g49) template showed that His170 offers an ideal hydrogen 
bonding interaction to the cortisol C20 carbonyl (Fig. 5A, Video 1). Due 
to the particular pKa properties of His170, it may also provide positive 
charge for compensating the negative charge of the cofactor’s phosphate 
groups. Furthermore, the human 11β-HSD2 model bears a charged 
glutamic acid at position 172 (Glu172) in close proximity to His170. 
Even though Glu172 is not directly involved in substrate binding, it may 
influence the structure of the protein considerably due to its charge and 
positioning preference towards the solvent. Interestingly, Glu172 was 
proposed earlier to interact with Leu179 and disruption of the stabili-
zation of a flexible turn in the AME causing mutant Leu179Arg may 
contribute to the observed loss of function (Yau et al. 2017). 
In contrast, the active site loop (residues 168–180) of mouse 11β- 
HSD2 contains more lipophilic residues (Leu170, Ile172) compared to 
the human structure (Fig. 5B, Video 2). These two lipophilic residues 
were predicted to hide from the solvent into the interior of the active site 
cavity, causing substantial reshaping of the backbone path in the area 
critical for substrate binding and slightly limiting the accessibility of the 
pocket. This still allowed binding of endogenous substances like cortisol, 
but bulky compounds like itraconazole, OHI and posaconazole (Suppl. 
Fig. 2) may experience less favorable interactions in the mouse 
compared to the human enzyme. For the reasons described above, we 
aimed to investigate to which extent the residues at position 170 and 
172 are involved in the observed species-dependent 11β-HSD2 inhibi-
tion by the studied azole antifungals. 
3.5. Effect of residues at positions 170 and 172 on the inhibition of 
human and mouse 11β-HSD2 by azole fungicides 
To test the relevance of the residues at positions 170 and 172 for the 
azole fungicide-dependent inhibition of human 11β-HSD2, His170 and 
Glu172 were mutated to the respective residues in mouse 11β-HSD2 
(Leu170, Ile172) in human wild type 11β-HSD2 (chimera E) or in the 
human enzyme bearing the mouse C-terminal region (chimera G) 
(Fig. 3B). The analogous exchange in mouse wild type (chimera F) and 
Fig. 3. Schematic representation of the cloned 11β-HSD2 mutants. Human sequence is indicated in black, mouse sequence in grey and the positions 170, 172, 276 
and 279 are represented by white bars. All sequences were cloned into pcDNA3 and carry a C-terminal FLAG-tag. 
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mouse 11β-HSD2 bearing the human C-terminus (chimera H) were 
constructed as well. The chimeric enzymes were well expressed and 
active in intact HEK-293 cells, except of chimera G that seemed to be 
unstable as indicated by its reduced expression following detection by 
western blot and based on the loss of enzyme activity in assays using 
lysates of HEK-293 cells transiently expressing chimera G (Supp. Fig. 1). 
Human 11β-HSD2 with the substitution His170Leu,Glu172Ile 
(chimera E) displayed significantly decreased inhibition by the three 
azole fungicides tested at 1 μM (Fig. 6). The analogous mutation 
Leu170His,Ile172Glu in the murine enzyme (chimera F) significantly 
increased and tended to increase the sensitivity towards itraconazole 
and OHI, respectively. In contrast, chimera F and mouse 11β-HSD2 were 
similarly inhibited by posaconazole. Importantly, replacing the C-ter-
minal region in the mouse sequence by that from human and introducing 
substitutions Leu170His,Ile172Glu (chimera H) changed the inhibition 
pattern for the three azole antifungals almost to that of the human 
enzyme (Fig. 6). Unfortunately, the combination of replacing the C- 
terminus of the human enzyme by that of the mouse and introducing 
substitutions His170Leu,Glu172Ile (chimera G), was not stable and 
could thus not be tested. 
Next, concentration-dependence curves were determined for the 
most potent 11β-HSD2 inhibitor, itraconazole (Fig. 7). Whilst an IC50 of 
itraconazole for human 11β-HSD2 of 121 ± 30 nM was obtained, a more 
than 15-fold weaker inhibition (2.17 ± 1.66 μM) was determined for 
chimera E carrying the His170Leu,Glu172Ile substitution (Table 2). 
Exchange of the human C-terminus by that of the mouse (chimera A) 
decreased the inhibitory potency of itraconazole by a factor of 30 (IC50 
value of 3.55 ± 1.81 μM). The combination of C-terminus exchange and 
His170Leu,Glu172Ile substitution could not be assessed due to the 
instability of chimera G. The murine enzyme showed a residual activity 
of about 95% at the highest itraconazole concentration tested (30 μM) 
and an IC50 value could not be determined. Regarding mouse 11β-HSD2, 
a gain of sensitivity towards inhibitory effect of itraconazole could be 
observed by replacing the C-terminal region by that from human 
(chimera B, 58% residual enzyme activity at 30 μM) or by introducing 
the substitution Leu170His,Ile172Glu (chimera F) (IC50 value of 6.34 ±
Fig. 4. Effect of the substitution of the C-terminal region of human and mouse 11β-HSD2 on azole fungicide-mediated inhibition. Lysates of HEK-293 cells expressing 
the indicated 11β-HSD2 construct were incubated for 10 min (human, chimera B) or 20 min (mouse, chimera A) with 50 nM cortisol, 500 μM NAD+ and 1 μM or 10 
μM of test substances. Substrate conversion was normalized to vehicle control (0.4% DMSO). Data from three independent experiments represent mean ± SD. Two- 
way ANOVA with Bonferroni’s post hoc test, p values: * < 0.05, **** < 0.0001 and ns (not significant), n.d. (not detected). 
Fig. 5. Predicted binding of cortisol (green) and NAD+ (orange) to 11β-HSD2. A) human and B) mouse 11β-HSD2 homology models. Dashed yellow lines indicate 
relevant hydrogen bond interactions (fulfilling directionality and distance criteria <2.8 Å) for protein-ligand binding. (For interpretation of the references to colour 
in this figure legend, the reader is referred to the web version of this article.) 
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3.83 μM). Most importantly, exchange of the mouse C-terminus by that 
of the human enzyme in combination with the substitution Leu170His, 
Ile172Glu (chimera H), displayed a humanized phenotype, with an IC50 
value of 561 ± 85 nM. Similar results were found for posaconazole 
(Fig. 7 and Table 2): the IC50 for chimera B and F were about two and 
three times lower than for the mouse enzyme, respectively. Substitution 
Leu170His,Ile172Glu in combination with the introduction of the 
human C-terminus (chimera H) further reduced the IC50. Moreover, 
posaconazole was about three times less effective to inhibit chimera E 
and approximately 7-fold less potent to inhibit chimera A compared to 
the human enzyme. 
4. Discussion 
Recent clinical studies and case reports evidenced that the systemi-
cally used azole antifungals posaconazole and itraconazole can cause 
pseudohyperaldosteronism (reviewed in (Beck et al. 2020b)). Two 
distinct mechanisms were proposed, namely inhibition of the adrenal 
cortisol synthesis by CYP11B1, which seems to be the predominant 
mechanism for posaconazole (Barton et al. 2018; Boughton et al. 2018; 
Kuriakose et al. 2018; Beck et al. 2020a), and inhibition of cortisol 
inactivation by 11β-HSD2 in the kidney and colon, which seems to be the 
predominant mode-of-action for itraconazole (Hoffmann et al. 2018; 
Beck et al. 2020b). These adverse effects have only recently been 
recognized in patients, mainly in those reaching high serum drug levels, 
and they have remained unrecognized in preclinical investigations. 
The present study revealed considerable species-specific differences 
in the inhibition of 11β-HSD2 by posaconazole, itraconazole and its 
main metabolite OHI. Regarding posaconazole, a very moderate differ-
ence of only 1.6-fold lower inhibitory activity was found against rat 
compared to human 11β-HSD2, in line with a previous estimation based 
on a comparison of human recombinant enzyme with whole rat kidney 
homogenate (Beck et al. 2017). Earlier toxicological studies in rats on 
the safety of posaconazole reported effects at high dose that were related 
to inhibition of steroid hormone synthesis; however, no information was 
provided on the underlying mechanism and typical symptoms of 
pseudohyperaldosteronism were not declared (European Medicines 
Agency 2019). Compared to posaconazole, itraconazole is a more potent 
inhibitor of human 11β-HSD2 (Beck et al. 2017). However, both itra-
conazole and its major metabolite OHI only moderately inhibited rat 
11β-HSD2, in line with the previous preliminary assessment comparing 
human recombinant enzyme with whole rat kidney homogenate (Beck 
et al. 2017). This earlier experiment could not exclude a degradation of 
itraconazole and OHI by renal drug metabolizing enzymes, thus the 
present comparison of recombinant enzymes of the different species in 
an identical cellular background was needed. Interestingly, preclinical 
repeated-dose toxicity studies in rats assessing the safety of itraconazole 
did not detect any significant alterations of endocrine parameters (Van 
Cauteren et al. 1987). The lower sensitivity of rat compared to human 
11β-HSD2 towards posaconazole and itraconazole may explain, at least 
in part, why pseudohyperaldosteronism as an adverse drug reaction has 
not been recognized in rodent preclinical studies. However, the differ-
ence in the inhibitory potency, especially of posaconazole, between rat 
and human 11β-HSD2 is very moderate and the reason why preclinical 
studies in rats did not reveal more pronounced effects on blood pressure 
and blood electrolytes are not fully understood. Further research should 
evaluate inter-individual as well as inter-species drug bioavailability. 
Regarding posaconazole, a recent study reported pseudohyperaldoster-
onism in only 20–25% of treated patients that also reached high serum 
concentrations (Nguyen et al. 2020). If rats exhibit a higher capacity to 
metabolize posaconazole and itraconazole than humans or if they have 
increased activity of efflux proteins, sufficiently high drug levels to 
inhibit 11β-HSD2 may not be reached in this species at the site of the 
target, i.e. kidney and adrenals. Both posaconazole and itraconazole also 
inhibit human CYP11B1 and CYP11B2; however, their inhibitory effects 
towards the rat enzymes remains to be determined. A lower inhibitory 
activity of these two azole antifungals towards rat CYP11B1 could also 
contribute to a lower risk for pseudohyperaldosteronism. 
Blood pressure and blood electrolyte are usually measured in pre-
clinical and clinical studies. If altered, pseudohyperaldosteronism could 
be detected by determination of serum renin and aldosterone. In case of 
low renin and aldosterone, further steroid analysis is indicated. 
Fig. 6. Comparison of the posaconazole-, itraconazole- and OHI-dependent inhibition of human and mouse 11β-HSD2 with that of chimera E, F and H. Lysates of 
HEK-293 cells expressing recombinant 11β-HSD2 of the indicated species or the respective chimera were incubated for 10 min (human) or 20 min (mouse, chimeras) 
with 50 nM cortisol, 500 μM NAD+ and 1 μM or 10 μM of the test compounds. Substrate conversion was normalized to that of the vehicle control (0.4% DMSO). Data 
represent mean ± SD from three independent experiments. Data were analyzed by two-way ANOVA with Bonferroni’s post hoc test. P values: * < 0.05, ** < 0.01, 
**** < 0.0001 and ns (not significant), n.d. (not detected). 
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Increased serum and urinary ratios of active to inactive glucocorticoids 
are indicative of 11β-HSD2 inhibition and elevated 11-deoxycortisol and 
11-deoxycorticosterone of CYP11B1 inhibition (Beck et al. 2020b). 
An additional safety concern represents the disruption of the 11β- 
HSD2-mediated placental glucocorticoid barrier between mother and 
fetus. Inhibition of placental 11β-HSD2 can lead to elevated fetal 
exposure to cortisol, affecting fetal programming. An observational 
study in pregnant Finnish woman, assessing the effect of licorice intake 
(containing the potent 11β-HSD2 inhibitor GA) on pregnancy duration 
and health of the children, detected shorter gestation times, reduced 
birth weight, as well as an increased HPA axis activity and behavioral 
disturbances in the childhood (Strandberg et al. 2002; Räikkönen et al. 
2009; Räikkönen et al. 2010). However, the use of azole antifungals is 
not indicated during pregnancy. 
Importantly, the present study demonstrates that posaconazole and 
itraconazole (including OHI) are very weak inhibitors of mouse and 
zebrafish 11β-HSD2, with IC50 values above 7 μM. Whilst the mouse 
represents the most widely used species for mechanistic investigations, 
including transgene lines, the zebrafish is a frequently used model or-
ganism that gained increasing interest due to the low cost and the fact 
Fig. 7. Concentration-dependent inhibition of 11β-HSD2 variants by itraconazole and posaconazole. Lysates of HEK-293 cells expressing recombinant 11β-HSD2 of 
the indicated species or the respective chimera were incubated for 10 min (human, chimera B) or 20 min (mouse, chimera A, E, F, H) with 50 nM radiolabeled 
cortisol, 500 μM NAD+ and increasing concentrations of itraconazole (A, B) and posaconazole (C, D). Substrate conversion was normalized to that of the vehicle 
control (0.6% DMSO for itraconazole and 0.3% DMSO for posaconazole). Data from three independent experiments are shown as mean ± SD. 
Table 2 
IC50 values for human and mouse 11β-HSD2 as well as for chimera A, B, E, F and 
H for itraconazole and posaconazole. 11β-HSD2 activity was determined in ly-
sates of HEK-293 cells expressing the indicated 11β-HSD2 variant, measuring the 
conversion of cortisol to cortisone in presence of increasing concentrations of 
inhibitor. Inhibition curves were fitted and analyzed by non-linear regression. 
Data were normalized to vehicle control and represent mean ± SD of at three 
independent experiments. * % remaining activity at highest concentration of 30 
μM.   
IC50 [μM]   
Itraconazole Posaconazole 
Human  0.121 ± 0.030 0.512 ± 0.079 
Mouse  (95%)* 8.212 ± 0.557 
Chimera A 3.55 ± 1.81 3.78 ± 1.58 
B (58%)* 4.80 ± 1.66 
E 2.17 ± 1.66 1.40 ± 0.45 
F 6.34 ± 3.83 2.77 ± 0.38 
H 0.561 ± 0.085 2.30 ± 0.61  
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that experiments with larvae are not considered as animal experiments 
(Planchart et al. 2016; Wrighton et al. 2019). Thus, mechanisms and 
possible consequences for human of 11β-HSD2 inhibition by these azole 
antifungals cannot be studied in these two species. Furthermore, as the 
concentrations of azole antifungals in the environment were reported to 
be in the picomolar range (Assress et al. 2019); the risk that itraconazole 
and posaconazole from wastewater affect fish health via 11β-HSD2 in-
hibition is negligible. Nevertheless, CYP11B1/2 that are also targets of 
posaconazole and itraconazole in human remain to be investigated as 
targets of these drugs in fish as well as in rodents (Beck et al. 2020a). 
This study emphasizes a cautious approach when trying to extrapolate 
findings from animal models to human. Species differences need to be 
taken into account when using animals as disease models or when 
investigating alternative 11β-HSD2 substrates, environmental inhibitors 
or potential therapeutic inhibitors. 
To begin to understand the species-specific differences in the inhi-
bition of 11β-HSD2 by the investigated azole antifungals, molecular 
modeling and chimeric enzymes with residue substitutions between 
human and mouse sequences were applied. As no 11β-HSD2 crystal 
structure is available to date, homology models were built for the human 
and mouse enzyme, based on human and guinea-pig 11β-HSD1 crystal 
structures, similar to previously reported models (Yamaguchi et al. 
2011a; Yamaguchi et al. 2011b). In contrast to a recently reported model 
based on 17β-HSD1 structure (Yau et al. 2017), our attempts failed to 
find a suitable binding pose of cortisol allowing electron transfer to 
NAD+ in 11β-HSD2 models derived from 17β-HSD1 structures. 
Furthermore, as shown in Fig. 8, superposition of 20 human homology 
models revealed the highly flexible C-terminal region for which no 
suitable structural prediction could be made due to the low similarity 
with any to-date crystallized protein. This emphasizes the uniqueness of 
the 11β-HSD2 C-terminal region compared to other short-chain dehy-
drogenase/reductase enzymes. 
The roles of Trp276 and Arg279, suggested previously to be involved 
in the different response of human and mouse 11β-HSD2 to itraconazole 
and posaconazole (Beck et al. 2017), are difficult to predict by using 
homology models. Nevertheless, the influence of the non-conserved 
eight amino-acid long sequence located upstream of Trp276 was 
investigated by exchanging this cassette between human and mouse 
11β-HSD2, followed by analysis of inhibitory effects. The observation 
that the exchange of this sequence did not alter the inhibition pattern for 
both chimeric enzymes compared to their wild type counterpart, 
suggests that a different positioning of Trp276 and Arg279 is not 
responsible for the observed species differences towards posaconazole 
and itraconazole. Alternatively, the substituted residues may not alter 
the different orientations of Trp276 and Arg279 in human and mouse 
11β-HSD2. 
Nevertheless, the C-terminal region had a partial effect on the 
species-specific inhibition of 11β-HSD2 by the studied azole antifungals. 
Itraconazole, its metabolite OHI and posaconazole have a prolonged 
rigid shape composed of consecutive rings, whereby the extended moi-
ety of the molecule is oriented into the binding pocket to compete with 
the substrate and the rest of the molecule faces the C-terminal region of 
the enzyme (approximately 60% of the structure). In order to elucidate 
how such large rigid molecules can interact with residues in the C-ter-
minal region, crystal structures with the cofactor and either cortisol or 
the respective inhibitor will be needed. 
Besides the C-terminus, the active site loop comprising residues 
168–180 was found to be responsible for part of the differences in the 
azole fungicide-mediated inhibition of 11β-HSD2 between human and 
mouse. The weak inhibition of mouse 11β-HSD2 by these compounds 
suggests that the lipophilic residues Leu170 and Ile172 at the analogous 
position of His170 and Glu172 in the human enzyme might cause steric 
hindrance, preventing the binding at this particular site. The homology 
model of mouse 11β-HSD2 can accommodate endogenous substrates like 
cortisol, but the bulky terminal groups of itraconazole and posaconazole 
are predicted to experience less favorable interactions compared to the 
human enzyme (Fig. 9, Video 3 and Video 4). In the human model, 
residue Glu172 is charged and expected to be oriented towards the 
solvent, leaving more room for bulky lipophilic ligands, while the 
amphiphilic character of histidine can be exploited. Substitution of 
Ile172 by glutamate in the mouse enzyme might induce conformational 
changes by reorientation of Glu172 to the solvent, thus increasing the 
size of the binding cavity, which consequently allows inhibition by the 
studied azole antifungals. Indeed, if the two residues 170 and 172 were 
mutated in the human enzyme to those present in mouse (chimera E), a 
substantial drop of inhibitory potency of itraconazole, OHI and pos-
aconazole was seen. On the other hand, increased inhibition was 
observed, when the amino acids at position 170 and 172 in the mouse 
enzyme were changed to those in the human enzyme (chimera F). 
Interestingly, a synergistic gain of inhibitory effect of itraconazole 
was observed when the mouse enzyme was mutated to bear the human 
C-terminal region and the Leu170His,Ile172Glu substitution. This 
chimeric enzyme represented the inhibitory pattern of human 11β- 
HSD2, indicating that both, residues in close proximity of the substrate 
and cofactor as well as residues in the C-terminal region, are involved in 
the potent inhibition by itraconazole. Interestingly, an interaction of the 
backbone of Asn171 with Arg279 located in the C-terminal region was 
proposed earlier to be important for the activity of the human enzyme 
(Yau et al. 2017). Asn171 was also proposed earlier to stabilize the 
binding of substrates (Fürstenberger et al. 2012) or of amino acids that 
interact with the pyrophosphate moiety of the cofactor (Arnold et al. 
2003). Itraconazole and posaconazole might disturb such interactions 
and consequently inhibit human 11β-HSD2 activity. Whether mutation 
of the rat enzyme, or the zebrafish enzyme that is less conserved, at these 
positions leads to a humanized phenotype remains to be investigated. 
In conclusion, the present study revealed significant species-specific 
differences in the inhibition of 11β-HSD2 by the azole antifungals itra-
conazole and posaconazole that have been missed in preclinical studies 
using rodents and that would also not be detected using zebrafish as an 
animal model. Predictions based on homology modeling and analysis of 
chimeric enzymes showed that substitution of Leu170,Ile172 in mouse 
11β-HSD2 by the corresponding residues of the human enzyme, i.e. 
His170,Glu172, along with the exchange of the C-terminal region 
resulted in a gain of sensitivity towards inhibitory effect of these azole 
antifungals to resemble the pattern observed for the human enzyme. The 
derived structure-activity relationship information should facilitate 
follow-on studies to assess drugs with the potential to cause 11β-HSD2- 
Fig. 8. Superposition of 20 human 11β-HSD2 homology models. Alpha helices 
are represented in red and beta sheets as arrows in turquoise. Itraconazole 
(green) and the cofactor NAD+ (orange) were docked into the binding pocket. 
The high variability of the predicted C-terminal region is indicated by the un-
structured grey lines. (For interpretation of the references to colour in this 
figure legend, the reader is referred to the web version of this article.) 
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dependent pseudohyperaldosteronism, and it should also be useful for 
the design of 11β-HSD2 inhibitors for specific therapeutic application 
and selection of adequate experimental animal models. In order to 
improve modeling-based predictions, mature artificial intelligence al-
gorithms like AlphaFold capable of predicting the fold as well as crystal 
structures of 11β-HSD2 from different species in the presence of cofactor 
and substrate or inhibitor will be needed. 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.taap.2020.115387. 
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